Podcast 2: Monoclonal antibody treatment for atopic dermatitis

In this episode Professor Jacob Thyssen is joined by Professor Andreas Wollenberg to discuss new and emerging treatment options for atopic dermatitis including the recent approval of the monoclonal antibody tralokinumab in Europe and the United States. They describe clinical data from Phase 2 clinical trials, discuss safety profiles, and highlight the importance of tailoring treatment for the patient in the face of the evolving treatment landscape. In addition, the professors discuss the pathophysiology of atopic dermatitis including the possible relevance of cytokines in disease management.